[go: up one dir, main page]

CL2023001223A1 - Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo - Google Patents

Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo

Info

Publication number
CL2023001223A1
CL2023001223A1 CL2023001223A CL2023001223A CL2023001223A1 CL 2023001223 A1 CL2023001223 A1 CL 2023001223A1 CL 2023001223 A CL2023001223 A CL 2023001223A CL 2023001223 A CL2023001223 A CL 2023001223A CL 2023001223 A1 CL2023001223 A1 CL 2023001223A1
Authority
CL
Chile
Prior art keywords
preparing
crystal form
receptor agonist
melanocortin receptor
agonist compound
Prior art date
Application number
CL2023001223A
Other languages
English (en)
Inventor
Ok HAM Jin
Yeon Lee Ho
Yoon Kim Ji
Won Kim Sung
Ah CHUN Seul
Dae Lee Sang
Won Park Jong
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2023001223A1 publication Critical patent/CL2023001223A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a la forma cristalina I de un compuesto representado por la fórmula química 1, a un procedimiento para su preparación y a una composición farmacéutica que lo comprende. La forma cristalina I del compuesto representado por la fórmula química 1 de la presente invención puede caracterizarse por un patrón XRD, un perfil DSC y/o un perfil TGA.
CL2023001223A 2020-10-29 2023-04-27 Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo CL2023001223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200142396 2020-10-29

Publications (1)

Publication Number Publication Date
CL2023001223A1 true CL2023001223A1 (es) 2023-11-03

Family

ID=81384109

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001223A CL2023001223A1 (es) 2020-10-29 2023-04-27 Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo

Country Status (14)

Country Link
US (1) US20230373984A1 (es)
EP (1) EP4219472A4 (es)
JP (1) JP2023548327A (es)
KR (2) KR102672624B1 (es)
CN (1) CN116507615A (es)
AU (1) AU2021367713B2 (es)
CA (1) CA3195298A1 (es)
CL (1) CL2023001223A1 (es)
CO (1) CO2023006515A2 (es)
IL (1) IL302427A (es)
MX (1) MX2023004655A (es)
PE (1) PE20240048A1 (es)
WO (1) WO2022092909A1 (es)
ZA (1) ZA202305594B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024501828A (ja) * 2020-12-22 2024-01-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
WO2022139446A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법
WO2022139443A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 i 및 이의 제조방법
CA3217168A1 (en) * 2021-05-06 2022-11-10 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
CN117242063A (zh) * 2021-05-07 2023-12-15 株式会社Lg化学 黑皮质素受体激动剂化合物与香兰素的共晶及其制备方法
AU2022271120A1 (en) * 2021-05-07 2023-11-09 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
MX2023013128A (es) * 2021-05-07 2023-11-28 Lg Chemical Ltd Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1187614A4 (en) * 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
JP2004521117A (ja) 2001-01-23 2004-07-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
CA2545644C (en) 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Melanocortin receptor agonists
KR20080007046A (ko) * 2006-07-14 2008-01-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
MX2019009463A (es) 2017-02-08 2019-12-16 Tilray Inc Metodo y aparatos para procesamiento de canabis a traves de energia radiante de baja presion.
PH12021553170A1 (en) * 2019-11-07 2022-08-15 Lg Chemical Ltd Melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
EP4219472A4 (en) 2024-03-13
KR20240085230A (ko) 2024-06-14
CN116507615A (zh) 2023-07-28
AU2021367713A9 (en) 2024-04-18
IL302427A (en) 2023-06-01
ZA202305594B (en) 2024-09-25
AU2021367713B2 (en) 2024-01-25
MX2023004655A (es) 2023-05-18
EP4219472A1 (en) 2023-08-02
KR102672624B1 (ko) 2024-06-07
US20230373984A1 (en) 2023-11-23
PE20240048A1 (es) 2024-01-09
CA3195298A1 (en) 2022-05-05
CO2023006515A2 (es) 2023-07-31
KR20220057470A (ko) 2022-05-09
AU2021367713A1 (en) 2023-06-01
WO2022092909A1 (ko) 2022-05-05
JP2023548327A (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
CL2023001223A1 (es) Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006517A2 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
UY33317A (es) Nuevos derivados de pirazol
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
AR066158A1 (es) COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
UY36746A (es) Método para la síntesis de derivados de rapamicina
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
CL2021002205A1 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
CL2023001221A1 (es) Agonista del receptor de melanocortina-4 amorfo
DOP2021000074A (es) Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contiene la misma
CO2020006206A2 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
BR112023022863A2 (pt) Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
BR112015031945A2 (pt) processos para a preparação de compostos
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
MX2023013129A (es) Forma cristalina iv de sales de acidos organicos del compuesto agonista del receptor de melanocortina y metodo de preparacion de este.
BR112018009029A8 (pt) corante, método para a produção de um corante, composição, artigo manufaturado e uso de um corante
BR112023022334A2 (pt) Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas